Identification and validation of COX-2 as a co-target for overcoming cetuximab resistance in colorectal cancer cells

Cetuximab, an epidermal growth factor receptor (EGFR)-blocking antibody, was approved for treatment of metastatic colorectal cancer over a decade ago; however, patients' responses to cetuximab vary substantially due to intrinsic and acquired resistance to cetuximab. Here, we report our findings...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yang, Shi, Chunmei, Qiu, Songbo, Fan, Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323114/
https://www.ncbi.nlm.nih.gov/pubmed/27074568
http://dx.doi.org/10.18632/oncotarget.8649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323114/
https://www.ncbi.nlm.nih.gov/pubmed/27074568
http://dx.doi.org/10.18632/oncotarget.8649

Ejemplares similares